BUSINESS

Towa Begins Priority Supply of 23 APIs, Mostly under Shipment Curbs, to Quake-Hit Area

By Takashi Ebisawa January 26, 2024

Big 3 Japanese generic manufacturer Towa Pharmaceutical has started supplying 39 products spanning 23 APIs, predominantly under shipment restrictions, on a priority basis to central Japan areas affected by the New Year’s earthquake.

On January 18, the Ishikawa Pharmaceutical Association directly urged the health minister to lift such restrictions within Ishikawa Prefecture, which was hit the hardest by the temblor. The Ministry of Health, Labor and Welfare (MHLW) soon responded by issuing a notification asking that shipment-restricted drugs be supplied with priority to the prefecture and other such areas.

Towa had already made priority supply arrangements for some of its shipment-controlled products with high needs to the quake-hit Hokuriku region by utilizing drugs in stock that had been manufactured in a ramp-up to address generic shortages as well as its emergency inventories.

The day after the association’s direct plea, the company presented a list of 23 APIs/39 products to the pharmacist group, then on January 25, it started their priority supplies by providing batches of medicines to partner wholesalers, asking them to decide which disaster areas should receive the drugs.

Of the 39 products, 38 are under shipment restrictions, including the cough medicine dextromethorphan, expectorant carbocysteine, antipyretic analgesic acetaminophen, montelukast, a treatment for bronchial asthma and allergic rhinitis, as well as antibiotic clarithromycin. The flu agent oseltamivir is the only product among the 39 not affected by shipment curbs.

Related Article

BUSINESS

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…

By Ken Yoshino

As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…